Towards a best-in-class IgE disruptor for food allergy with Claude-enabled antibody design
Food allergy affects an estimated 220-250 million people worldwide, for whom the constant risk of a severe reaction weighs heavily on quality of life. Allergic reactions are triggered by the cross-linking of allergen-specific IgE bound to its high-affinity receptor, Fc{epsilon}RI, on mast cells and basophils, causing degranulation, inflammation and, in severe cases, anaphylaxis. Omalizumab…
Food allergy afflicts an estimated 220-250 million people across the globe, imposing a significant burden on their quality of life. The allergic response is instigated by the aggregation of allergen-specific IgE that binds to its high-affinity receptor, Fc{epsilon}RI, on mast cells and basophils. This triggers degranulation, inflammation, and in extreme cases, anaphylaxis.
Currently, omalizumab (Xolair), the only FDA-approved biologic for food allergy, functions by neutralizing circulating IgE; however, it fails to effectively eliminate IgE from Fc{epsilon}RI, where it can persist for weeks and still trigger sensitivity with minimal residual amounts.
In an effort to develop a more effective IgE disruptor, a team used an agentic computational design process with Claude. Claude pursued a biparatopic molecule, combining a disruptor arm to displace IgE from Fc{epsilon}RI and a non-competing anchor arm to keep the molecule bound to receptor-bound IgE. Out of 91 experimentally characterized disruptor designs, 20 displayed activity against receptor-bound IgE through competitive bio-layer interferometry.
Among these, three variants proved to be more effective than omalizumab at therapeutically relevant concentrations (25-400 nM).
Additionally, the de novo designs for the anchor arm demonstrated the ability to bind IgE at various epitopes, with apparent affinities ranging from 3.4 to 235 nM. These subcomponents serve as the foundation for further characterization, with the ultimate goal of creating a best-in-class IgE disruptor.
Rewritten by urgent.news; may contain errors — check the original.
Source: biorxiv.org